Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDP870 + MTX in RA Partial Responders
NCT00544154Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2002
- Primary completion
- Jan 2004
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Oct 2002; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00544154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00544154.